Minimal residual disease: Detection, clinical relevance, and treatment strategies

Journal of Hematotherapy and Stem Cell Research

Volumn 5, Issue 5, 1996, Pages 537-548

  Dwenger, Anne ^a   Lindemann, Albrecht ^a   Mertelsmann, Roland ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; T LYMPHOCYTE RECEPTOR; TUMOR VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENE THERAPY; GENETIC TRANSDUCTION; LYMPHOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; REVIEW; SOLID TUMOR; SOUTHERN BLOTTING; VACCINATION;

HUMANS; NEOPLASM, RESIDUAL; NEOPLASMS;

EID: 0029853403     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.1.1996.5.537     Document Type: Article

References (102)

1. Tkachuk, D.C., Westbrook, C.A., Andreef, M., et al. Detection of BCR-ABL fusion in chronic myelogenous leukemia by two-color fluorescence in situ hybridization. Science 250:559, 1990.
2. Brugger, W., Bross, K.J., Glatt, M., et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636, 1994.
3. Noguchi, S., Aihara, T., Motomura, K., et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am. J. Pathol. 148:649, 1996.
4. Yamada, M., Wasserman, R., Reichard, B.A., et al. Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. J. Exp. Med. 173:395, 1991.
5. Yamada, M., Hudson, S., Tournay, O., et al. Detection of minimal residual disease in hematopoietic malignancies of the B-cell lineage by using third-complementary-determining region (CDR III)-specific probes. Proc. Natl. Acad. Sci. USA 86:5123, 1989.
6. Deane, M., Hoffbrand, A., Prentice, H.G., et al. Detection of minimal residual disease in B lineage leukaemia by immunoglobulin gene fingerprinting. Heam. Blood Transfus. 34:178, 1992.
7. Miyamura, K., Tanimoto, M., Morishima, Y., et al. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation. Blood 79:1366, 1992.
8. Beishuizen, A., Verhoeven, M.A.J., van Wering, E.R., et al. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: Implication for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 83:2238, 1994.
9. Brisco, M.J., Condon, J., Hughes, E., et al. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantitation of residual disease at the end of induction. Lancet 343:196, 1994.
10. Cave, H., Guidal, C., Rohrlich, P., et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 83:1892, 1994.
11. Ito, Y., Wasserman, R., Galili, N., et al. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 11:546, 1993.
12. Biondi, A., Yokota, S., Hansen-Hagge, T.E., et al. Minimal residual disease in childhood acute lymphoblastic leukemia: Analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 6:282, 1992.
13. Adriaansen, H.J., Jacobs, B.C., Kappers-Klunne, M.C., et al. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal desoxynucleotidyl transferase and myeloid markers. Leukemia 7:472, 1993.
14. Maruyama, F., Stass, S.A., Estey, E.H., et al. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 8:40, 1994.
15. Miller, W.H., Levine, K., DeBlasio, A., et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha mRNA. Blood 82:1687, 1994.
16. Kusec, R., Laczika, K., Knobl, P., et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735, 1994.
17. Nucifora, G., Larson, R.A. & Rowley, J.D. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type m2 in long-term remission. Blood 82:712, 1993.
18. Miller, W.H. Jr., Levine, K., DeBlasio, A., et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 82:1264, 1993.
19. Biondi, A. & Rambaldi, A. Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia. Stem Cells 12:394, 1994.
20. Brenner, M.K., Rill, D.R., Moen, R.C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85, 1993.
21. Roth, M.S., Antin, J.H., Ash, R., et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 79:276, 1992.
22. Hughes, T.P., Morgan, G.J., Martiat, P., et al. Detection of residual leukemia after bone marrow transplantation for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse. Blood 77:874, 1991.
23. Cross, N.C.P., Hughes, T.P., Feng, L., et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Correlations with acute graft-versus-host disease and relapse. Br. J. Haematol. 84:67, 1993.
24. Van Rhee, F., Lin, F., Cross, N.C.P., et al. Detection of residual leukemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transplant. 14:609, 1994.
25. Miyamura, K., Tahara, T., Tanimoto, M., et al. Long-persistent bcr-abl-positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients. Blood 81:1089, 1993.
26. Pichert, G., Alyea, E.P., Soiffer, R.J., et al. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood 84:2109, 1994.
27. Verfaillie, C.M., Miller, W.J., Boylan, K., et al. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003, 1992.
28. Deisseroth, A.B., Zu, Z., Claxton, D., et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 82:3068, 1994.
29. Lambrechts, A.C., Hupkes, P.E., Borssers, L.C.J., et al. Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J. Clin. Oncol. 12:1541, 1994.
30. Gribben, J.G., Neuberg, D., Barber, M., et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800, 1994.
31. Hardingham, J.E., Kotasek, D., Sage, R.E., et al. Significance of molecular marker-positive cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 13:1073, 1995.
32. Johnson, P.W.M., Price, C.G.A., Smith, T., et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J. Clin. Oncol. 12:798, 1994.
33. Liu, Y., Hernandez, A.M., Shibata, D., et al. Bcl-2 translocation frequency rises with age in humans. Proc. Natl. Acad. Sci. USA 91:8910, 1994.
34. Gribben, J.G., Freedman, A.S., Neuberg, D., et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation of B-cell lymphoma. N. Engl. J. Med. 325:1525, 1991.
35. Gribben, J.G., Neuberg, D., Freedman, A.S., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449, 1993.
36. Pantel, K., Schlimok, G., Angstwurm, M., et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J. Hematother. 3:165, 1994.
37. -7. Proc. Natl. Acad. Sci. USA 92:537, 1995.
38. Lindemann, F., Schlimok, G., Dirschedl, P., et al. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340:685, 1992.
39. Sharp, J.G. Micrometastases and transplantation. J. Hematother. 5:519, 1996.
40. Cote, R.J., Rosen, P.P., Lesser, M.L., et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol. 9:1749, 1991.
41. Pantel, K., Izbicki, J.R., Angstwurm, M., et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. 53:1027, 1993.
42. Diel, I.J., Kaufmann, R., Goerner, R., et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant matastasis. J. Clin. Oncol. 10:1534, 1992.
43. Rill, D.R., Santans, V.M., Roberts, W.M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994.
44. Ross, A.A., Cooper, B.W., Lazarus, H.M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605, 1993.
45. Mertelsmann, R. The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: Achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells. Eur. Cytokine Network 6:79, 1995.
46. Golumbek, P., Lazenby, A., Levitsky, H., et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713, 1991.
47. Douvdevani, A., Huleihel, M., Zoller, M., et al. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int. J. Cancer 51:822, 1992.
48. Apte, R.N., Douvdevani, A., Zoller, M., et al. Cytokine-induced tumor immunogenicity: Endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunol. Lett. 39:45, 1993.
49. Visseren, M.J.W., Koot, M., van der Voort, E.I.H., et al. Production of interleukin-2 by EL-4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J. Immunother. 15:119, 1994.
50. Gansbacher, B., Zier, K., Daniels, B., et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217, 1990.
51. Stingl, G., Brocker, E.D., Mertelsmann, R., et al. Phase I study of the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with human IL-2 gene. Human Gene Then 7:551, 1996.
52. Osanto, S., Brouwestyn, N., Vaessen, N., et al. Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Human Gene Ther. 4:323, 1993.
53. Cassileth, P.A., Podack, E., Sridhar, K., et al. Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Human Gene Ther. 6:369, 1995.
54. Patel, P.M., Flemming, C.L., Russell, S.J., et al. Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour. Br. J. Cancer 68:295, 1993.
55. McBride, W.H., Thacker, J.D., Comora, S., et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res. 52:3931, 1992.
56. Kruger-Krasagakes, S., Li, W., Richter, G., et al. Eosinophils infiltrating interleukin-5-gene-transfected tumors do not suppress tumor growth. Eur. J. Immunol. 23:992, 1993.
57. Berns, A.J.M., Clift, S., Cohen, L.K., et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF-gene transduction in patients with metastatic renal cell carcinoma. Human Gene Ther. 6:347, 1995.
58. Asher, A.L., Mule, J.J., Kasid, A., et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3227, 1991.
59. Blankenstein, T., Qin, Z., Uberla, K., et al. Tumor suppression after tumor cell-targeted tumor necrosis factor-α gene transfer. J. Exp. Med. 162:2163, 1991.
60. Qin, Z., Kruger-Krasagakes, S., Kunzendorf, U., et al. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented matastasis. J. Exp. Med. 178:355, 1993.
61. Walther, W., Fichtner, I. & Uckert, W. Retrovirus-mediated gene transfer of tumor necrosis factor alpha into colon carcinoma cells generates a growth inhibition. Anticancer Res. 13:1565, 1993.
62. Porgador, A., Bannerji, R., Watanabe, Y., et al. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J. Immunol. 150:1458, 1993.
63. Matsuda, M., Salazar, F., Petersson, M., et al. Interleukin 10 pretreatment protects target cells from tumor- and allospecific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 180:2371, 1994.
64. Richter, G., Kruger-Krasagakes, S., Hein, G., et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53:4134, 1993.
65. Veelken, H., Jesuiter, H., Mackensen, A., et al. Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy. Human Gene Then 5:1205, 1994.
66. Mertelsmann, R., Lindemann, A., Boehm, T., et al. Pilot study for the evaluation of T-cell-mediated tumor im-munotherapy by cytokine gene transfer in patients malignant tumors. J. Mol. Med. 73:205, 1995.
67. Restifo, N.P., Kawakami, Y., Marincola, F., et al. Molecular mechanisms used by tumor cells to escape immune recognition: Immunotherapy and the cell biology of major histocompatibility complex class I. J. Immunother. 14:182, 1993.
68. Yang, G., Hellstrom, K.E., Hellstrom, I., et al. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794, 1995.
69. Fraser, J.D., Irving, B.A., Crabtree, G.R., et al. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251:313, 1991.
70. Townsend, S.E. & Allison, J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368, 1993.
71. Chen, L., Ashe, S., Brady, W.A., et al. Costimulation of antitumor immunity by the B7 counterreceptor for T lymphocyte molecules CD28 and CTLA4. Cell 71:1093, 1992.
72. Guckel, B., Lindauer, M., Rudy, W., et al. CD80-transfected human breast and ovarian tumor cell lines: Improved immunogenicity and induction of cytolytic CD8+ T lymphocytes. Cytokine Mol. Ther. 1:211, 1995.
73. Baskar, S., Ostrand-Rosemberg, S., Nabavi, N., et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687, 1993.
74. Cayeux, S., Beck, C., Aicher, A., et al. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25:2325, 1995.
75. Inaba, K., Metlay, J.P., Crowley, M.T., et al. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC restricted T cells in situ. J. Exp. Med. 172:631, 1990.
76. Mittelman, A., Chen, Z.J., Yang, H., et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA 89:466, 1992.
77. Durrant, L.G., Buckley, T.J.D., Denton, G.W.L., et al. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res. 54:4837, 1994.
78. Mandelboim, O., Vadai, E., Fridkin, E., et al. Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nature Med. 1:1179, 1995.
79. Mackinnon, S., Barnett, L., Heller, G., et al. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 83:3409, 1994.
80. Lister, J., Pincus, S.M., Rybka, W.B., et al. Adoptive immunotherapy immediately after peripheral blood stem cell transplantation does not adversely affect engraftment and results in amplified killer function post transplant. Blood 82:650a, 1993.
81. Hwu, P., Yannelli, J., Kriegler, M., et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J. Immunol. 150:4104, 1993.
82. Stancovski, I., Schindler, D.G., Waks, T., et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151:6577, 1993.
83. Qi, Y., Moyana, T., Bresalier, R., et al. Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice. Gastroenterology 109:1950, 1995.
84. LoBuglio, A.F., Wheeler, R.H., Trang, J., et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc. Natl. Acad. Sci. USA 86:4220, 1989.
85. Pantel, K., Schlimok, G., Braun, S., et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl. Cancer Inst. 85:1419, 1993.
86. Riethmüller, G., Schneider-Gadicke, E., Schlimok, G., et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343:1177, 1994.
87. Schlimok, G., Fackler-Schwalbe, I., Pantel, K., et al. Monoclonal Lewis Y antibody depletes metastatic breast carcinoma cells from bone marrow. Proc. Am. Soc. Clin. Oncol. 12:299 (abstract), 1993.
88. Masucci, G. & Mellstedt, H. Combinations of IL-2, GM-CSF, IL-4, IFN-a and TNF-a increase the antibody dependent cellular cytotoxicity (ADCC) of blood mononuclear cells in presence of either mouse or chimeric MAb 17-1A - A preclinical evaluation. Cancer J. 4:168, 1991.
89. Maloney, D.G., Liles, T.M., Czerwinski, D.K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457, 1994.
90. Van de Winkel, J.G.J. & Capel, P.J.A. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications. Immunol. Today 14:215, 1993.
91. Chen, J., Zhou, J.H., Mokotoff, M., et al. Lysis of small cell carcinoma of the lung (SCCL) cells by cytokine-activated monocytes and natural killer cells in the presence of bispecific immunoconjugates containing a gastrin-releasing peptide (GRP) analog or a GRP anatgonist. J. Hematother. 4:369, 1995.
92. Ball, E.D., Guyre, P.M., Mills, L., et al. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: Cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM18) and anti-CD64/FcγRI (MoAb 32). J. Hematother. 1:85, 1992.
93. Repp, R., Valerius, T., Wieland, G., et al. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FcγRI and Her-2/neu (MDX-210). J. Hematother. 4:415, 1995.
94. Valone, F.H., Kaufman, P.A., Guyre, P.M., et al. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpress HER-2/neu. J. Hematother. 4:471, 1995.
95. Canevari, S., Mezzanzanica, D., Mazzoni, A., et al. Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions. J. Hematother. 4:423, 1995.
96. De Gast, G.C., Van Houten, A.A., Haagen, I.A., et al. Clinical experience with CD3 X CD19 bispecific antibodies in patients with B cell malignancies. J. Hematother. 4:433, 1995.
97. Mack, M., Riethmüller, G. & Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 92:7021, 1995.
98. Kroesen, B.J., Buter, J., Sleijfer, D.Th., et al. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer 70:652, 1994.
99. Bohlen, H., Manzke, O., Patel, B., et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res. 53:4310, 1993.
100. Winkler, U., Gottstein, C., Schön, G., et al. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 83:466, 1994.
101. Press, O.W., Eary, J.F., Appelbaum, F.R., et al. Radiolabeled antibody therapy of B cell lymphomas with autologous bone marrow support. N. Engl. J. Med. 329:1219, 1993.
102. Shpall, E.J., Bearman, S.I., Franklin, W.A., et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J. Clin. Oncol. 12:28, 1994.